menu
    • menu
    [{"orgOrder":0,"company":"MEDICIS PHARMACEUTICAL CORP","sponsor":"MEDICIS PHARMACEUTICAL CORP","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"NETHERLANDS","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Dermatology","graph2":"Phase IV","graph3":"MEDICIS PHARMACEUTICAL CORP","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"MEDICIS PHARMACEUTICAL CORP \/ MEDICIS PHARMACEUTICAL CORP","highestDevelopmentStatusID":"11","companyTruncated":"MEDICIS PHARMACEUTICAL CORP \/ MEDICIS PHARMACEUTICAL CORP"},{"orgOrder":0,"company":"MEDICIS PHARMACEUTICAL CORP","sponsor":"MEDICIS PHARMACEUTICAL CORP","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Neurology","graph2":"Phase IV","graph3":"MEDICIS PHARMACEUTICAL CORP","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"MEDICIS PHARMACEUTICAL CORP \/ MEDICIS PHARMACEUTICAL CORP","highestDevelopmentStatusID":"11","companyTruncated":"MEDICIS PHARMACEUTICAL CORP \/ MEDICIS PHARMACEUTICAL CORP"},{"orgOrder":0,"company":"MEDICIS PHARMACEUTICAL CORP","sponsor":"MEDICIS PHARMACEUTICAL CORP","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"MEDICIS PHARMACEUTICAL CORP","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"MEDICIS PHARMACEUTICAL CORP \/ MEDICIS PHARMACEUTICAL CORP","highestDevelopmentStatusID":"11","companyTruncated":"MEDICIS PHARMACEUTICAL CORP \/ MEDICIS PHARMACEUTICAL CORP"},{"orgOrder":0,"company":"MEDICIS PHARMACEUTICAL CORP","sponsor":"MEDICIS PHARMACEUTICAL CORP","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibiotic","year":"2010","type":"Inapplicable","leadProduct":"Clindamycin Phosphate","moa":"Bacterial 70S ribosome","graph1":"Dermatology","graph2":"Phase IV","graph3":"MEDICIS PHARMACEUTICAL CORP","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"MEDICIS PHARMACEUTICAL CORP \/ MEDICIS PHARMACEUTICAL CORP","highestDevelopmentStatusID":"11","companyTruncated":"MEDICIS PHARMACEUTICAL CORP \/ MEDICIS PHARMACEUTICAL CORP"},{"orgOrder":0,"company":"MEDICIS PHARMACEUTICAL CORP","sponsor":"MEDICIS PHARMACEUTICAL CORP","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Fluocinonide","moa":"Glucocorticoid receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"MEDICIS PHARMACEUTICAL CORP","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"MEDICIS PHARMACEUTICAL CORP \/ MEDICIS PHARMACEUTICAL CORP","highestDevelopmentStatusID":"11","companyTruncated":"MEDICIS PHARMACEUTICAL CORP \/ MEDICIS PHARMACEUTICAL CORP"},{"orgOrder":0,"company":"MEDICIS PHARMACEUTICAL CORP","sponsor":"MEDICIS PHARMACEUTICAL CORP","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Fluocinonide","moa":"Glucocorticoid receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"MEDICIS PHARMACEUTICAL CORP","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"MEDICIS PHARMACEUTICAL CORP \/ MEDICIS PHARMACEUTICAL CORP","highestDevelopmentStatusID":"8","companyTruncated":"MEDICIS PHARMACEUTICAL CORP \/ MEDICIS PHARMACEUTICAL CORP"}]

    Find Clinical Drug Pipeline Developments & Deals by MEDICIS PHARMACEUTICAL CORP

    Menu

    MEDICIS PHARMACEUTICAL CORP

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            MEDICIS PHARMACEUTICAL CORP

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            MEDICIS PHARMACEUTICAL CORP

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Botulinum toxin type A

                            Therapeutic Area : Dermatology

                            Study Phase : Phase IV

                            Recipient : The Maas Clinic

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Onabotulinum Toxin Type A and Abobotulinum Toxin Type A Crow's Feet Rhytid Study

                            Details : Botulinum Toxin Type A is a Protein drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Skin Aging.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            February 09, 2012

                            Lead Product(s) : Botulinum toxin type A

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase IV

                            Recipient : The Maas Clinic

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            MEDICIS PHARMACEUTICAL CORP

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            MEDICIS PHARMACEUTICAL CORP

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fluocinonide

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Recipient : Wake Forest University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy of Fluocinonide Cream 0.1% (Vanos(R)) in Reducing Itch in Subjects With Atopic Dermatitis

                            Details : Fluocinonide is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Dermatitis, Atopic.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 10, 2011

                            Lead Product(s) : Fluocinonide

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Recipient : Wake Forest University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            MEDICIS PHARMACEUTICAL CORP

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            MEDICIS PHARMACEUTICAL CORP

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Botulinum toxin type A

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase IV

                            Recipient : Kenneth Beer

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Brow Lifting With Dysport

                            Details : Botulinum Toxin Type A is a Protein drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Blepharoptosis.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            July 25, 2011

                            Lead Product(s) : Botulinum toxin type A

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase IV

                            Recipient : Kenneth Beer

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            MEDICIS PHARMACEUTICAL CORP

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            MEDICIS PHARMACEUTICAL CORP

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Botulinum toxin type A

                            Therapeutic Area : Neurology

                            Study Phase : Phase IV

                            Recipient : Beer, Kenneth R., M.D., PA

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Upper Facial Remodeling With Perlane-L and Dysport

                            Details : Botulinum Toxin Type A is a Protein drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Temporal Atrophy.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            May 17, 2011

                            Lead Product(s) : Botulinum toxin type A

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase IV

                            Recipient : Beer, Kenneth R., M.D., PA

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            MEDICIS PHARMACEUTICAL CORP

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            MEDICIS PHARMACEUTICAL CORP

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fluocinonide

                            Therapeutic Area : Dermatology

                            Study Phase : Phase IV

                            Recipient : Wake Forest University Health Sciences

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study Evaluating the Efficacy of Fluocinonide Cream 0.1% (Vanos) in Subjects With Atopic Dermatitis

                            Details : Fluocinonide is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Dermatitis, Atopic.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 14, 2010

                            Lead Product(s) : Fluocinonide

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase IV

                            Recipient : Wake Forest University Health Sciences

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            MEDICIS PHARMACEUTICAL CORP

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            MEDICIS PHARMACEUTICAL CORP

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Clindamycin Phosphate

                            Therapeutic Area : Dermatology

                            Study Phase : Phase IV

                            Recipient : Wake Forest University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Adherence to Study Medication Compared to Generic Topical Clindamycin Plus Generic Topical Tretinoin in Subjec...

                            Details : Clindamycin Phosphate is a Antibiotic drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Acne Vulgaris.

                            Product Name : Undisclosed

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            January 12, 2010

                            Lead Product(s) : Clindamycin Phosphate

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase IV

                            Recipient : Wake Forest University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth